Extracellular matrix building marked by the N-terminal propeptide of procollagen type I reflect aggressiveness of recurrent breast cancer

被引:35
|
作者
Jensen, BV [1 ]
Johansen, JS
Skovsgaard, T
Brandt, J
Teisner, B
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2700 Herlev, Denmark
[2] Hvidovre Univ Hosp, Dept Rheumatol, Copenhagen, Denmark
[3] Odense Univ, Dept Immunol & Microbiol, DK-5230 Odense M, Denmark
关键词
extracellular matrix; collagen metabolism; amino-terminal propeptide of type I procollagen; advanced breast cancer; prognostic factors; survival;
D O I
10.1002/ijc.10187
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of our study was to examine the association between extracellular matrix homeostasis and aggressive breast cancer as reflected by the synthesis of type I collagen marked by circulating concentration of the aminoterminal propeptide of type 1 procollagen (PINP). Pre-therapeutic serum PINP concentrations were measured in 154 healthy women and 100 patients referred with their first metastatic manifestation of breast cancer and correlated to the metastatic pattern, response to therapy, time to progression and survival with a minimal follow-up of 5 years. Fifty-four percent of the patients had serum PINP concentrations greater than the 95th percentile of the healthy controls and 38% were high PINP level patients with values clearly outside normal range (> 125 ng/ml). Patients with high PINP levels were more sick (p = 0.002), had a higher tumor burden (p = 0.013) and revealed a lower responsiveness to anthracycline-based therapy (p = 0.0002) as well as an accelerated time to disease progression (p = 0.00001) and death (p = 0.0006). Median survival in the high serum PINP level group was less than half of that in the group with low PINP level (14.5 vs. 32 months). The lowest PINP levels were seen when the cancer was restricted to the lymph node and skin and increasing PINP levels were found if the cancer had spread to the lungs to the bones, the bone marrow and the liver. High PINP level at recurrence and lack of estrogen receptors (ER) independently reflected aggressive tumor behavior after recurrence with an equal great impact on time to progression and survival. Patients with a high PINP level and primarily ER-negative tumors survived a median of only 6 months with no one alive after 22 months. By contrast patients with a low PINP level and ER-positive tumors had a median survival of 37 months and 23% were still alive after 5 years. Aggressive breast cancer induces a strong fibroproliferative response with synthesis of type I collagen. Serum PINP levels may be a diagnostic and prognostic tool that indicate breast cancer activity, aggressiveness, expansion and metastasis and a predictor of outcome after anthracycline-based chemotherapy. (C) 2002 Wiley-Liss. Inc.
引用
收藏
页码:582 / 589
页数:8
相关论文
共 50 条
  • [41] Intra-Individual Changes in Total Procollagen-Type 1 N-terminal Propeptide in a Korean Adult Population
    Choi, Rihwa
    Lee, Sang Gon
    Lee, Eun Hee
    DIAGNOSTICS, 2022, 12 (10)
  • [42] N-Terminal Propeptide of Type III Procollagen (P3NP) Responses to Resistance Exercise in Older Adults
    Fragala, Maren S.
    Jajtner, Adam R.
    Beyer, Kyle S.
    Wells, Adam J.
    Townsend, Jeremy R.
    Emerson, Nadia S.
    Scanlon, Tyler C.
    Stout, Jeffrey R.
    Oliveira, Leonardo P.
    Hoffman, Jay R.
    FASEB JOURNAL, 2013, 27
  • [43] Assessing bone formation in patients with chronic kidney disease using procollagen type I N-terminal propeptide (PINP): The choice of assay makes a difference
    Tridimas, Andreas
    Milan, Anna
    Marks, Eileen
    ANNALS OF CLINICAL BIOCHEMISTRY, 2021, 58 (05) : 528 - 536
  • [44] Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis
    Lee, YJ
    Shin, KC
    Kang, SW
    Lee, EB
    Kim, HA
    Song, YW
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2001, 19 (01) : 69 - 74
  • [45] α-interferon improves liver fibrosis in chronic hepatitis C -: Clinical significance of the serum N-terminal propeptide of procollagen type III
    Serejo, F
    Costa, A
    Oliveira, AG
    Ramalho, F
    Batista, A
    De Moura, MC
    DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (08) : 1684 - 1689
  • [46] The fibrosis biomarkers procollagen type III, N-terminal propeptide and transforming growth factor β1 as foes for patients with atrial fibrillation
    Tao, Hui
    Cao, Wei
    Shi, Kai-Hu
    AMERICAN HEART JOURNAL, 2014, 168 (04)
  • [47] STRUCTURE OF ANTIGENIC DETERMINANTS IN THE N-TERMINAL REGION OF DERMATOSPARACTIC SHEEP PROCOLLAGEN TYPE-I
    ROHDE, H
    TIMPL, R
    BIOCHEMICAL JOURNAL, 1979, 179 (03) : 643 - 647
  • [48] The phenotypic features of osteogenesis imperfecta resulting from a mutation of the carboxyl-terminal pro alpha 1(I) propeptide that impairs the assembly of type I procollagen and formation of the extracellular matrix
    Cole, WG
    Chow, CW
    Bateman, JF
    Sillence, DO
    JOURNAL OF MEDICAL GENETICS, 1996, 33 (11) : 965 - 967
  • [49] The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone
    Koizumi, M
    Yonese, J
    Fukui, I
    Ogata, E
    BJU INTERNATIONAL, 2001, 87 (04) : 348 - 351
  • [50] Oncological validation of bone turnover markers c-terminal telopeptide of type I collagen (1CTP) and peptides n-terminal propeptide of type I procollagen (P1NP) in patients with prostate cancer and bone metastases
    Aufderklamm, Stefan
    Hennenlotter, Joerg
    Rausch, Steffen
    Bock, Cornelia
    Erne, Eva
    Schwentner, Christian
    Stenzl, Arnulf
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 4000 - 4008